Background and Objectives: Second-generation drug-eluting stents (G2-DES) are
rate of acute and subacute stent thrombosis in G2-DES that has previously been reported in the literature. have been developed to overcome residual safety concerns from firstgeneration drug-eluting stent (DES), [1] [2] [3] [4] delayed reendothelialization is still considered to be an inevitable safety matter in any type of DES. [5] [6] [7] [8] [9] [10] In particular, the safety of DES in acute and subacute phases in cases of ST-segment elevation myocardial infarction (STEMI) was debated as a result of the activated thrombogenicity, 11, 12 instability of residual plaque, 13 and higher frequency of suboptimal results in the procedure. 14, 15 However, contrary to expectations, a lower rate of definite stent thrombosis with an everolimus-eluting stent (EES) compared with the bare-metal stent (BMS) was demonstrated in the EXAMINATION (clinical Evaluation of the Xience-V stent in Acute Myocardial INfArc-TION) trial. 16 Surprisingly, the difference in the rate of thrombosis between the groups was most significant in acute and subacute phases.
Although it may be favorable in all aspects of clinical practice, the mechanisms and factors underlying the fewer thrombotic events with G2-DES compared with BMS in the early phase after acute myocardial infarction (AMI) remain unclear. Thus, the aim of this study was to compare the vascular response and thrombus burden between G2-DES and BMS in early-phase STEMI, using optical coherence tomography (OCT).
| MATERIALS AND METHODS

| Study population
This is an observational study conducted in a single center (Depart- T or I) increased to greater than the upper reference. 17 Cases with bypass graft lesions, stent thrombosis, and intolerance to antiplatelet drugs and contrast dye were excluded from the analysis. All patients provided written informed consent for all of the interventional procedures in the present study. The study protocol was approved by the ethics committee of our institution. 
| PCI procedure for STEMI
| OCT image acquisition and analysis
The OCT follow-up was performed at 3 or 6 weeks after the initial PCI for STEMI. The follow-up timing was completely dependent on the PCI for nonculprit lesions. OCT images were acquired using frequency greater than 100 μm for Xience Prime, Xience Xpedition, and
Multi-link 8, greater than 110 μm for Integrity and Driver, and greater than 115 μm for Liberté. The well-apposed coverage was calculated as well-apposed struts with neointima divided by total struts. A thrombus was defined as an irregular protruding of signal-rich, lowbackscattering protrusions or high-backscattering protrusions beyond the stent struts into the lumen, with signal-free shadowing and a sharp intensity gap with a dimension of greater than or equal to 250 μm on the OCT image. 21, 22 Percent thrombus length was calculated as the thrombus length divided by the stent length. Thrombus burden was defined as the mean thrombus area divided by the mean lumen area.
A semiquantitative assessment was also performed using the OCTthrombus score. A thrombus was classified as absent (0) or subtending 1, 2, 3, or 4 quadrants in each cross section. 23 Thrombus score was calculated as the sum of each score ( Figure 2 ). In the evaluation of apposition and NIH, overlapping stents and bifurcation lesions with major side branches were excluded from the analysis. Evaluation of % thrombus includes overlapping and bifurcation lesions with major side branches. Other definitions are described in the Supporting Information.
| Statistical methods
Categorical variables were reported as counts (%) and compared by the χ 2 test. The average with standard deviation was reported when the data were normally distributed, and the median with interquartile range was reported when the data were not normally distributed. Continuous variables were compared by the t test when the data were normally distributed and compared by the Mann-Whitney U test when the data were not normally distributed. All tests were two-sided, and statistical significance was defined as P < 0.05. All statistical analyses were performed using JMP 9.0 version (SAS Institute, Cary, North Carolina).
3 | RESULTS
| Patient characteristics
There were no significant differences in baseline clinical characteristics between the DES group and the BMS group other than a higher age in the BMS group (Table 1) . Baseline lesion and procedural characteristics including the incidence of residual thrombus evaluated by final IVUS images after the stent implantation were comparable between patients with DES and BMS ( Table 2 ). Medications at discharge are shown in Table 3 . All those medications were prescribed with the same dose and type until follow-up.
| NIH at 1 month
A total of 966 cross sections and 9871 struts were analyzed (Table 4) . No significant difference was observed between the DES 
| DISCUSSION
The main findings of the present study are the following: (1) Thrombus burden and thrombus score were significantly smaller in DES than in BMS at 1-month follow-up in STEMI patients, (2) the rate of malapposed and uncovered struts was comparable between DES and BMS at the 1-month follow-up, and (3) no significant differences in thrombus burden or the rate of uncovered struts was observed between EES and E-ZES at 1-month follow-up. 
| Thrombogenicity and stent characteristics
The causes of thrombus formation and subsequent clinical events after coronary stent implantation are considered to be the accumulation of unfavorable factors in patient (eg, diabetes and hereditary drug withdrawal), procedural (eg, suboptimal stenting), device (eg, metal and polymer), lesion (eg, residual thrombus and lipid-rich plaque), and pharmacological responses to antiplatelet drugs. [24] [25] [26] [27] [28] Renewed technologies in G2-DES such as biocompatible polymers, improved drugeluting kinetics, thinner struts, and a well-designed platform with better conformability may contribute to the reduction of thrombus formation and clinical events compared with first-generation DES and BMS. [1] [2] [3] [4] Although the exact mechanism of smaller thrombus burden in G2-DES compared with BMS in the present study still remains unclear, the presence of biocompatible polymer in G2-DES might play an important role as a protective factor for thrombus formation, among several differences between them. The polymer in DES is a carrier of eluted drug and has several characteristics that improve biocompatibility of the stent through anti-inflammatory and antithrombotic effects. [29] [30] [31] [32] Previous studies demonstrated that polymer coating provides thromboresistance through the modification of surface properties such as electrostatic forces, hydrophilic interaction, and roughness. [33] [34] [35] In particular, the fluoropolymer in Xience-EES was designed to have better biocompatibility for blood and vascular tissues compared with that in older stents. [36] [37] [38] Another study investigating vascular responses to Xience-EES early after the implantation in STEMI also demonstrated a decreased thrombus volume, although the authors mentioned that the combination of multiple factors, including biocompatible polymer, contributed to the favorable vascular behavior. 39 These results may alleviate the safety concern for a shorter duration of dual antiplatelet therapy in patients receiving Xience-EES; this is currently being tested in a clinical trial named
STOPDAPT-2 (ShorT and OPtimal Duration of Dual AntiPlatelet
Therapy-2) (ClinicalTrials.gov identifier: NCT02619760).
From findings in previous studies, strut thickness is considered to be an important factor for the thrombogenicity of coronary stents. 40 However, we think that the impact of strut thickness on the results in the present study was limited because we found a difference in thrombus burden among stents having a similar platform with thin struts. In addition to stent characteristics, vascular responses including neointimal coverage, strut malapposition, tissue protrusion, 13 and dissection may cause focal thrombus formation and subsequent clinical events, particularly in patients with acute coronary syndrome. 41 However, in the present study, the incidence of those findings on OCT images was comparable between the groups. Taken together, the presence of polymer in G2-DES might be the major contributor, among various others, to the smaller thrombus burden compared with BMS in the early phase after implantation.
| Thrombogenic properties among DES types
A significant difference in thrombus burden was not observed between EES and E-ZES in the present study, although previous Although Orsiro-SES has a circumferential polymer in addition to the thinner strut than that in the Xience-EES, the result was worse in
Orsiro compared with Xience-EES. 29 In the Orsiro stent, the polymer was composed of a hybrid coating with passive PROBIO amorphous silicon carbide (Biotronik) and active BIOlute bioabsorbable poly-Llactide acid coating (Biotronik). In contrast, the polymer in Xience-EES was poly(n-butyl methacrylate) (PBMA) encapsulated by a poly(vinylidene fluoride-co-hexafluoropropylene) (PVDF-HFP). PVDF-HFP (used on Xience-EES) retained more albumin and platelet interaction behavior than PBMA and polystyrene-b-polyisobutylene-b-polystyrene (used on Taxus Liberté-PES). 32 Thus, the difference in protein and surface materials may be attributed to the different properties in antithrombogenicity between the two DES. The polymer in E-ZES was 2-methacryloyloxyethyl phosphorylcholine (MPC). MPC could significantly decrease platelet adhesion and prolong clotting time because the tightly bound water layer forms a physical and energetic barrier to prevent protein adsorption and platelet adhesion on the surface. [42] [43] [44] Thus, the antithrombogenic property of E-ZES might be equivalent to EES. In fact, there was no significant difference in acute or subacute thrombosis between DES and ZES at 1-year follow-up in a meta-analysis of clinical trials. 45 
| Limitations
Several limitations in this study require acknowledgment. First, this is a nonrandomized observational study conducted in a single center with a limited number of patients. Second, as an observational study, a formal sample size calculation was not performed, and thus, the study may be underpowered. Third, the residual thrombus was not volumetrically evaluated at the end of the primary procedure by OCT. Differences in residual thrombus volume among groups might have affected the results.
| CONCLUSION
Thrombus burden was significantly smaller with DES than with BMS at 1-month follow-up in STEMI cases, although the percentage of EES, everolimus-eluting stent; E-ZES, zotarolimus-eluting stent. P value was calculated by Mann-Whitney U test. The box represents the interquartile range and the line in the box, the median. Whiskers represent 1.5 IQR uncovered struts was similar between the groups. This may partly explain the lower rate of acute and subacute stent thrombosis in G2-DES that has been shown in previous studies.
